![]() |
市場調查報告書
商品編碼
2098418
輸尿管鏡設備市場-2026-2032年全球市場預測Ureteroscopy Devices Market - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,輸尿管鏡設備市場將成長至 38 億美元,複合年成長率為 7.33%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 23.1億美元 |
| 預計年份:2026年 | 24.7億美元 |
| 預測年份 2032 | 38億美元 |
| 複合年成長率 (%) | 7.33% |
輸尿管鏡設備是現代內視鏡泌尿系統的核心,它透過直接觀察輸尿管和腎臟集合系統,實現尿道結石、狹窄、腫瘤和上泌尿道異常的微創診斷和治療。此類別包括硬式、半硬式、軟式和一次性輸尿管鏡、影像系統、入路鞘套、導管導引線、取石籃、雷射光纖、灌注系統以及在手術室和門診手術中使用的輔助器具。市場需求的促進因素包括泌尿系統尿道結石的高臨床負擔、對器官保留和微創手術的日益青睞、數位成像技術的進步以及雷射碎石平台的日益普及。在臨床實踐中,人們越來越傾向於使用直徑更小、柔韌性更高、解析度更高、配備晶片式數位成像技術、灌注控制更佳且透過一次性或混合設備策略降低感染風險的輸尿管鏡。採購決策受多種因素影響,包括耐用性、影像品質、維修頻率、消毒需求、外科醫生效率、與體外震波碎石能源來源的兼容性以及手術總擁有成本。隨著醫療系統優先考慮縮短住院時間、降低併發症發生率和加速患者康復,輸尿管鏡設備正成為結石治療和上泌尿道介入治療中不可或缺的工具。
輸尿管鏡器械的市場格局正在重塑,傳統可重複使用的光學設備正逐漸被數位化軟性輸尿管鏡、一次性內視鏡和整合式泌尿系統平台所取代。隨著臨床管治中對器械再處理的複雜性、內視鏡維修成本、交叉感染問題以及手術安排效率等問題的日益關注,醫院正在重新審視其器械組合。一次性輸尿管鏡在感染風險高的環境、急診病例以及消毒能力有限的醫療機構中變得越來越重要。同時,在維護和生命週期管理可以最佳化的醫療機構中,可重複使用的數位系統仍然至關重要。雷射碎石術領域也出現了明顯的技術創新,钬:YAG雷射系統仍然被廣泛使用,而铥光纖雷射器因其預期具有更精確的碎石能力、更小的後推力以及更高的碎石效率而日益普及。微型化技術拓展了進入解剖結構複雜部位的途徑,而鞘套、鎳鈦合金取石籃和親水性導管的改進則有助於更安全地進行手術操作和取石。永續性也成為關鍵考量因素,醫療專業人員除了評估感染控制、物流和手術流程的一致性外,還需評估一次性內視鏡對環境的影響。監管機構對醫療設備可追溯性、滅菌驗證和臨床安全性記錄的要求,進一步強調了循證採購和標準化泌尿內視鏡泌尿系統流程的必要性。
人工智慧 (AI) 正透過影像增強、工作流程最佳化、臨床決策支援、訓練分析和手術記錄等方式,逐步影響輸尿管鏡設備。在內鏡視覺化方面,AI 軟體可輔助即時影像銳利化、結石邊界辨識、解剖結構突出顯示和自動影片分析,但其臨床應用仍需檢驗、獲得監管部門批准並與手術室系統整合。 AI 在術前規劃方面也具有實際價值,它結合影像、病患病歷、結石特徵和解剖風險因素,輔助病例選擇、手術策略制定和器械規劃。在培訓環境中,AI 驅動的影片回顧可以評估內視鏡操作、雷射安全、取石籃操作、黏膜損傷風險和手術效率,從而支持泌尿系統的基於能力的教育。在營運方面,AI 可以透過分析設備使用情況、維修記錄、消毒流程瓶頸和手術安排模式,改善庫存管理並減少停機時間。其累積影響已超越機器人和自動化領域,日益聚焦於建立互聯互通的內視鏡泌尿外科生態系統,利用來自診斷影像、醫療設備、電子健康記錄和品質指標的數據,以提高安全性、一致性和資源分配效率。產業領導者應認知到,人工智慧的採用不僅取決於技術創新,還取決於透明的演算法、可互通的資料泌尿系統、網路安全措施以及具有臨床意義的結果。
亞太地區正發展成為輸尿管鏡器械的重要市場,這主要得益於腎結石診斷率的上升、醫院基礎設施的擴建、專科醫生培訓的加強以及中國、印度、日本、韓國、東南亞國協和東協國家內鏡結石治療的普及。該地區的需求也受到飲食結構變化、都市化、代謝性疾病的流行、氣候相關的結石風險因素以及影像技術的推廣等因素的支撐,儘管都市區三級醫療機構和資源匱乏的醫療機構在輸尿管鏡器械的應用模式上存在差異。在北美,輸尿管鏡手術技術高度發達,這得益於內視鏡泌尿系統領域的先進技術、門診手術的普及、微創手術的醫保報銷以及數位軟式內視鏡、雷射碎石術和感染控制方案的廣泛應用。拉丁美洲的主要都市區正在大力發展內視鏡泌尿系統,其中巴西和墨西哥是重要的治療中心。然而,醫療資源分配不均、預算限制以及公共部門的採購週期正在影響設備的選擇。在歐洲,臨床實務中,微創泌尿外科技術的應用已較為成熟,這得益於基於指南的結石管理、眾多醫療系統集中採購、嚴格的消毒標準以及對患者安全、永續性和成本效益的高度重視。在中東,對先進外科基礎設施的投資正在穩步推進,微創泌尿系統服務也不斷擴展,尤其是在高所得海灣國家的醫療體系中,這主要得益於醫療旅遊和專科醫學的現代化。非洲的情況則更為複雜,腎結石治療的需求日益成長,但內視鏡泌尿系統設備、訓練有素的專家以及維護支援方面的資源分配卻存在差異。最大的商機在於那些公私合作投資、培訓夥伴關係以及耐用醫療設備策略能夠確保價格合理和服務連續性的地區。
在東南亞國協,隨著醫療體系擴容以容納更多專科醫生,微創泌尿系統正日益受到重視。其普及受到多種因素的影響,包括對都市區醫院的投資、對可負擔性的需求、熱帶氣候下特有的結石負擔,以及在公私混合醫療環境下對能夠處理大量治療的醫療設備的需求。海灣合作理事會(GCC)國家的特點是大力投資醫院現代化,偏好先進的內視鏡系統,並專注於高品質的臨床基礎設施,其中感染預防、數位化可視化和與整合手術室的兼容性是關鍵的採購因素。歐盟的特點是嚴格的標準主導環境,輸尿管鏡設備的普及受到臨床指南、醫療設備法規、採購流程透明度、再處理合規性以及對永續性的關注的影響。金磚國家是一個多元化但具有重要戰略意義的群體,其龐大的患者群體、診斷服務的普及、對國內生產的重視以及不斷提升的外科手術能力正在推動輸尿管鏡技術的更廣泛應用。然而,報銷機制、地方供應政策以及醫院資源的差異正在影響技術的普及速度。在七國集團(G7)國家,軟性輸尿管鏡檢查、雷射碎石術、門診手術路徑以及以品質為中心的採購系統普遍較為成熟,採購決策通常基於臨床證據、生命週期成本、設備可靠性和感染控制能力。北約成員國的醫療保健體係水準參差不齊,從先進到新興不等,但隨著數位內視鏡平台對資料的依賴性和互通性日益增強,國防相關供應鏈的韌性、互聯設備的網路安全預期以及醫院的緊急應變準備標準變得愈發重要。
美國在輸尿管鏡設備的普及應用方面處於全球領先地位,這得益於其龐大的手術量、完善的門診手術基礎設施、充足的專科醫生以及對數位影像、雷射碎石和感染控制的高度重視。在加拿大,基於指南的結石管理得到持續實踐,公共醫療採購優先考慮臨床價值、設備再處理能力以及州際間公平的醫療服務取得。在墨西哥,受私立醫療機構發展、影像檢查普及以及對經濟高效醫療系統的需求推動,各大都會圈醫院的泌尿系統視鏡技術正在不斷擴展。巴西擁有大規模的泌尿系統治療基礎,並由三級醫療中心和專科培訓體系提供支持,但公共採購的限制仍影響著設備的取得。在英國,標準化的臨床路徑、醫療技術評估和手術室資源的有效利用備受重視,並支持在臨床需要的情況下,基於循證醫學證據推廣使用可重複使用和一次性輸尿管鏡平台。德國憑藉其先進的醫院基礎設施、高超的外科技術以及對工程品質和消毒性能的高度重視,在泌尿外科領域佔據優勢。法國則將基於指南的實踐與嚴謹的公共採購相結合。俄羅斯的內視鏡泌尿系統技術應用受到區域醫療現代化、本地供應鏈以及主要醫療中心與偏遠地區之間醫療資源分配不均等因素的影響。義大利和西班牙擁有成熟的泌尿內視鏡技術體系,其醫療設備選擇受公立醫院預算、外科醫生偏好和手術效率等因素的影響。中國透過醫院擴建、國產醫療設備的研發以及對尿路結石認知的提高,在泌尿系統視鏡領域取得了快速發展。印度由於龐大的患者群體、氣候和飲食等尿路結石風險因素以及不斷擴大的私人醫院網路,長期需求強勁,但價格和醫療服務的可及性仍然是關鍵挑戰。日本擁有先進的臨床技術、人口老化帶來的泌尿系統需求以及對精密儀器的偏好。澳洲擁有領先的內視鏡泌尿外科技術應用體系,這得益於其專業的醫療中心和對醫療設備安全性的高標準。在韓國,競爭環境的特徵是積極採用數位醫療技術、醫院醫療能力強、微創泌尿系統護理不斷創新。
產業領導者應優先考慮以實證醫學為基礎的產品開發,重點關注影像品質、內視鏡耐用性、人體工學操作、彎曲穩定性、灌注性能、雷射相容性以及降低感染風險。鑑於醫院越來越傾向於比較整個手術流程的價值,而不僅僅是採購成本,產品系列應同時滿足可重複使用和一次性使用的需求。製造商和經銷商應加強臨床教育項目,內容涵蓋安全操作、雷射設定、取石籃使用、輸尿管損傷預防、消毒流程以及術後品質指標。供應鏈策略應包括可靠供應導管導引線、入路鞘套、取石籃和雷射光纖等耗材,因為手術的連續性取決於系統的完全就緒狀態。相關人員應投資於監管文件、真實世界數據 (REW) 收集和上市後監測,以增強臨床醫生和採購團隊之間的信任。鑑於人工智慧驅動的視覺化和分析日益重要,數位化整合的設計應圍繞互通性、網路安全和操作易用性。永續性必須透過生命週期評估、負責任的包裝、高效的再加工以及透明的環境聲明來解決。在新興市場,分階段的產品線、可維護性、培訓夥伴關係、靈活的資金籌措以及提供適合當地基礎設施條件的耐用醫療設備是成功的關鍵。
本執行摘要採用系統的二手研究方法檢驗,使用了經驗證的臨床、監管和行業相關資訊來源,包括泌尿系統指南、同行評審的醫學文獻、公共衛生出版物、醫療設備監管文件、醫院採購考量以及公認的臨床實踐標準。分析重點在於輸尿管鏡器械使用中的定性市場動態、技術進步、區域應用研究途徑、醫療基礎設施趨勢和操作考慮。資訊評估標準包括與泌尿系統泌尿外科實踐的相關性、可靠資訊來源的一致性以及對醫療設備策略、採購和臨床部署的適用性。本調查方法著重於循證洞察和策略解讀,因此不涉及市場規模計算、市場佔有率估算和預測。關鍵主題整合於醫療設備類別、治療環境、區域醫療保健系統以及新興技術領域,例如數位內視鏡、一次性內視鏡、雷射碎石術、感染預防和人工智慧驅動的工作流程支援。以說明格式呈現區域、群體和國家/地區特定見解,以提高搜尋可見性,並為相關人員提供與決策直接相關的背景資訊。
輸尿管鏡設備正從獨立儀器發展成為整合式、數據驅動的泌尿外科內泌尿系統解決方案,支持更安全、更快速、更穩定的尿道結石和上泌尿道手術。市場格局的形成受到以下因素的影響:人們對微創治療途徑、數位化視覺化、一次性產品應用、雷射碎石術創新、感染控制的重視以及人工智慧驅動的臨床工作流程的日益關注。不同地區之間存在顯著差異。成熟的醫療體系優先考慮臨床證據、生命週期成本和治療質量,而新興的醫療體系則更注重可及性、可負擔性、培訓和基礎設施。最具前景的策略機會在於將醫療設備創新與實際臨床需求結合。具體而言,這些需求包括可靠的可視化、高效的結石清除、減少併發症、簡化再處理或處置流程,以及為醫院和患者帶來可衡量的價值。那些能夠將強大的技術、培訓、服務支援、嚴格的監管合規性和永續設計相結合的機構,將更有能力滿足全球對基於輸尿管鏡的有效醫療保健日益成長的需求。
The Ureteroscopy Devices Market is projected to grow by USD 3.80 billion at a CAGR of 7.33% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.31 billion |
| Estimated Year [2026] | USD 2.47 billion |
| Forecast Year [2032] | USD 3.80 billion |
| CAGR (%) | 7.33% |
Ureteroscopy devices are central to contemporary endourology, enabling minimally invasive diagnosis and treatment of urinary tract stones, strictures, tumors, and upper tract abnormalities through direct visualization of the ureter and renal collecting system. The category includes rigid, semi-rigid, flexible, and single-use ureteroscopes, visualization systems, access sheaths, guidewires, stone retrieval baskets, laser fibers, irrigation systems, and ancillary instruments used in operating rooms and ambulatory surgical environments. Demand is shaped by the high clinical burden of urolithiasis, rising preference for organ-preserving and minimally invasive procedures, improved digital imaging, and broader availability of laser lithotripsy platforms. Clinical practice has increasingly moved toward smaller-diameter scopes, enhanced deflection, high-definition and digital chip-on-tip visualization, improved irrigation control, and infection-risk reduction through disposable or hybrid device strategies. Procurement decisions are influenced by durability, image quality, repair frequency, sterilization requirements, surgeon ergonomics, compatibility with lithotripsy energy sources, and total cost of procedure ownership. As health systems emphasize shorter hospital stays, lower complication rates, and faster patient recovery, ureteroscopy devices are positioned as essential tools in stone management and upper urinary tract intervention.
The ureteroscopy devices landscape is being reshaped by the shift from conventional reusable optics toward digital flexible ureteroscopes, single-use endoscopes, and integrated endourology platforms. Hospitals are reassessing device portfolios as reprocessing complexity, scope repair costs, cross-contamination concerns, and procedure scheduling efficiency become more visible in clinical governance. Single-use ureteroscopes are gaining relevance in high-risk infection settings, emergency cases, and facilities with limited sterilization throughput, while reusable digital systems remain important for high-volume centers that can optimize maintenance and lifecycle management. Technology transformation is also visible in laser lithotripsy, where holmium:YAG systems remain widely used and thulium fiber laser adoption is increasing due to precise dusting capability, lower retropulsion, and potential efficiency benefits in stone fragmentation. Miniaturization is expanding access to challenging anatomy, and improvements in access sheaths, nitinol baskets, and hydrophilic guidewires are supporting safer navigation and stone retrieval. Sustainability has emerged as a balancing factor, with care providers evaluating the environmental implications of disposable scopes alongside infection prevention, logistics, and procedural consistency. Regulatory expectations for device traceability, sterilization validation, and clinical safety documentation are further reinforcing the need for evidence-based procurement and standardized endourology workflows.
Artificial intelligence is beginning to influence ureteroscopy devices through image enhancement, workflow optimization, clinical decision support, training analytics, and procedural documentation. In endoscopic visualization, AI-enabled software can support real-time image clarification, stone boundary recognition, anatomy highlighting, and automated video analysis, although clinical deployment remains dependent on validation, regulatory clearance, and integration with operating room systems. AI also has practical value in preoperative planning by combining imaging, patient history, stone characteristics, and anatomical risk factors to support case selection, operative strategy, and instrument planning. In training environments, AI-assisted video review can help assess scope handling, laser safety, basket manipulation, mucosal trauma risk, and procedural efficiency, supporting competency-based education for urologists. Operationally, AI can analyze device utilization, repair histories, sterilization bottlenecks, and case scheduling patterns to improve inventory management and reduce downtime. The cumulative impact is not limited to robotics or automation; it is increasingly centered on creating a connected endourology ecosystem where data from imaging, devices, electronic records, and quality metrics improves safety, consistency, and resource allocation. Industry leaders should recognize that AI adoption will depend on transparent algorithms, interoperable data infrastructure, cybersecurity safeguards, and clinically meaningful outcomes rather than technology novelty alone.
Asia-Pacific is advancing as a critical region for ureteroscopy devices due to rising kidney stone diagnoses, growing hospital infrastructure, expanding specialist training, and increasing access to endoscopic stone management in China, India, Japan, South Korea, Australia, and ASEAN countries. Regional demand is supported by dietary changes, urbanization, metabolic disease prevalence, climatic stone risk factors, and wider use of diagnostic imaging, while adoption patterns vary between tertiary urban hospitals and resource-constrained facilities. North America remains highly advanced in ureteroscopy practice, supported by strong endourology expertise, outpatient surgery utilization, reimbursement pathways for minimally invasive procedures, and broad availability of digital flexible scopes, laser lithotripsy, and infection-control protocols. Latin America is characterized by improving endoscopic urology capabilities in major urban centers, with Brazil and Mexico serving as important procedural hubs; however, access disparities, budget sensitivity, and public-sector procurement cycles influence device selection. Europe demonstrates mature clinical adoption, shaped by guideline-driven stone management, centralized procurement in many health systems, robust sterilization standards, and strong focus on patient safety, sustainability, and cost-effectiveness. The Middle East is seeing investment in advanced surgical infrastructure, particularly in high-income Gulf health systems where minimally invasive urology services are expanding alongside medical tourism and specialty care modernization. Africa presents a more heterogeneous environment, with growing need for kidney stone treatment but uneven access to endourology equipment, trained specialists, and maintenance support; opportunities are strongest where public-private investment, training partnerships, and durable device strategies address affordability and service continuity.
ASEAN countries are increasingly prioritizing minimally invasive urology as healthcare systems expand specialist capacity, with adoption influenced by urban hospital investment, affordability requirements, tropical-climate stone burden, and demand for devices that can withstand high procedural throughput in mixed public-private settings. The GCC is distinguished by strong investment in hospital modernization, preference for advanced endoscopic systems, and emphasis on premium clinical infrastructure, making infection prevention, digital visualization, and integrated operating room compatibility important procurement drivers. The European Union reflects a highly regulated and standards-led environment in which ureteroscopy device adoption is shaped by clinical guidelines, medical device regulation, procurement transparency, reprocessing compliance, and growing sustainability scrutiny. BRICS countries represent a diverse but strategically important group where large patient populations, expanding diagnostic access, domestic manufacturing priorities, and increasing surgical capacity support broader ureteroscopy utilization, although reimbursement, local supply policy, and hospital resource variation affect adoption speed. G7 countries generally show mature uptake of flexible ureteroscopy, laser lithotripsy, ambulatory surgical pathways, and quality-driven procurement, with purchasing decisions often based on clinical evidence, lifecycle cost, device reliability, and infection-control performance. NATO countries span advanced and emerging healthcare systems, but defense-aligned supply chain resilience, cybersecurity expectations for connected devices, and hospital readiness standards are increasingly relevant as digital endoscopy platforms become more data-dependent and interoperable.
The United States is a leading adopter of ureteroscopy devices, supported by high procedural volumes, outpatient surgical infrastructure, broad specialist availability, and strong emphasis on digital imaging, laser lithotripsy, and infection prevention. Canada shows consistent use of guideline-aligned stone management, with public healthcare procurement placing importance on clinical value, reprocessing capacity, and equitable access across provinces. Mexico is expanding endourology capabilities in major metropolitan hospitals, with demand influenced by private healthcare growth, rising imaging access, and the need for cost-effective systems. Brazil has a significant urology treatment base, and adoption is supported by tertiary care centers and specialist training, while public procurement constraints continue to shape device access. The United Kingdom emphasizes standardized clinical pathways, health technology assessment, and efficient use of operating theater resources, supporting evidence-based adoption of reusable and single-use ureteroscopy platforms where clinically justified. Germany benefits from advanced hospital infrastructure, strong surgical specialization, and high attention to engineering quality and sterilization performance. France combines guideline-based practice with public procurement discipline, while Russia's adoption is shaped by regional healthcare modernization, local supply considerations, and access differences between major centers and remote areas. Italy and Spain have mature endourology communities, with device decisions influenced by public hospital budgets, surgeon preference, and procedural efficiency. China is rapidly advancing in endoscopic urology through hospital expansion, domestic device development, and rising stone disease recognition. India has strong long-term need due to large patient volume, climatic and dietary stone risk factors, and expanding private hospital networks, while affordability and service reach remain central. Japan demonstrates high clinical sophistication, aging-population-related urology demand, and preference for precision instruments. Australia maintains advanced adoption supported by specialist centers and high standards for device safety. South Korea shows strong uptake of digital medical technologies, high hospital capability, and a competitive environment for minimally invasive urology innovation.
Industry leaders should prioritize evidence-driven product development focused on image quality, scope durability, ergonomic handling, deflection stability, irrigation performance, laser compatibility, and reduced infection risk. Product portfolios should address both reusable and single-use requirements, recognizing that hospitals increasingly compare total procedural value rather than acquisition cost alone. Manufacturers and distributors should strengthen clinical education programs covering safe access, laser settings, basket use, ureteral injury prevention, sterilization workflows, and post-procedure quality metrics. Supply chain strategies should include reliable availability of consumables such as guidewires, access sheaths, baskets, and laser fibers, since procedural continuity depends on complete system readiness. Stakeholders should invest in regulatory documentation, real-world evidence generation, and post-market surveillance to support trust among clinicians and procurement teams. Digital integration should be designed around interoperability, cybersecurity, and practical operating room usability, particularly as AI-enabled visualization and analytics become more relevant. Sustainability should be addressed through lifecycle assessment, responsible packaging, reprocessing efficiency, and transparent environmental claims. In emerging markets, success will depend on tiered offerings, serviceability, training partnerships, financing flexibility, and durable devices suited to local infrastructure conditions.
This executive summary is developed through a structured secondary-research approach using verified clinical, regulatory, and industry-relevant sources, including urology guidelines, peer-reviewed medical literature, public health publications, medical device regulatory materials, hospital procurement considerations, and recognized clinical practice standards. The analysis focuses on qualitative market dynamics, technology evolution, regional adoption factors, healthcare infrastructure trends, and operational considerations in ureteroscopy device use. Information was evaluated for relevance to endourology practice, consistency across credible sources, and applicability to device strategy, procurement, and clinical implementation. The methodology excludes market sizing, market share estimation, and forecasting to maintain focus on evidence-backed insights and strategic interpretation. Key themes were synthesized across device categories, procedure settings, regional healthcare systems, and emerging technology areas such as digital endoscopy, single-use scopes, laser lithotripsy, infection prevention, and AI-enabled workflow support. Regional, group, and country insights were integrated into narrative form to support search visibility and provide decision-ready context for industry stakeholders.
Ureteroscopy devices are evolving from standalone instruments into integrated, data-enabled endourology solutions that support safer, faster, and more consistent urinary stone and upper tract procedures. The market environment is being shaped by minimally invasive care pathways, digital visualization, single-use adoption, laser lithotripsy innovation, infection-control priorities, and growing interest in AI-supported clinical workflows. Regional dynamics differ significantly, with mature healthcare systems emphasizing clinical evidence, lifecycle cost, and procedural quality, while emerging systems focus on access, affordability, training, and infrastructure readiness. The strongest strategic opportunities will come from aligning device innovation with real-world clinical needs: reliable visualization, efficient stone clearance, reduced complications, streamlined reprocessing or disposal pathways, and measurable value for hospitals and patients. Organizations that combine robust technology, training, service support, regulatory discipline, and sustainable design will be best positioned to meet the expanding global need for effective ureteroscopy-based care.